Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists

Agents

  • Albiglutide (Tanzeum) (see Albiglutide): approved in 2014
  • Dulaglutide (Trulicity) (see Dulaglutide): approved in 2014
  • Exenatide (Byetta, Bydureon) (see Exenatide): approved in 2005/2012
  • Liraglutide (Victoza, Saxenda) (see Liraglutide): approved in 2010
  • Lixisenatide (Lyxumia in Europe, Adlyxin in the United States) (see Lixisenatide): approved in 2016
  • Semaglutide (Ozempic, Rybelsus, Wegovy) (see Semaglutide): approved in 2017

Indications

Type 2 Diabetes Mellitus (see Diabetes Mellitus)

  • xxxx

References

  • xxx